Publications by authors named "K Mileham"
Background: Patients with locally advanced non-small-cell lung cancer (NSCLC) who undergo concurrent chemotherapy and radiotherapy often experience synergistic toxicity, and local regional control rates remain poor. We assessed the activity and safety outcomes of primary tumour stereotactic body radiotherapy (SBRT) followed by conventional chemoradiotherapy to the lymph nodes and consolidation immunotherapy in patients with unresectable locally advanced NSCLC.
Methods: In this multicentre, single-arm, phase 2 trial, patients aged 18 years and older were enrolled at eight regional cancer centres in North Carolina and South Carolina, USA.
Treatment of non-small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anticancer effects of immune checkpoint inhibitors (ICI). However, only 20% of the patients with NSCLC benefit from ICIs, highlighting the need to uncover the mechanisms mediating resistance. By analyzing the overall survival (OS) and mutational profiles of 424 patients with NSCLC who received ICI treatments between 2015 and 2021, we determined that patients carrying a loss-of-function mutation in neurotrophic tyrosine kinase receptor 1 (NTRK1) had a prolonged OS when compared with patients with wild-type NTRK1.
View Article and Find Full Text PDFArticle Synopsis
- The IASLC has developed a new histological grading system for invasive lung adenocarcinoma (LUAD) that aims to predict distant metastases, particularly in the brain and bones, after surgery.
- A study analyzed data from 174 early-stage LUAD patients who underwent surgery, monitoring them for 5 years to assess metastasis-free survival rates.
- The findings suggest that the IASLC grading system is more effective than traditional grading methods in predicting the occurrence of distant metastases and could help identify high-risk patients post-surgery.
Article Synopsis
- High-grade immune-related adverse events (irAEs) can limit treatment options for patients with non-small cell lung cancer (NSCLC) and predicting these events is crucial for effective therapy management.
- A study analyzed 430 NSCLC patients who received immune checkpoint inhibitors (ICIs) to evaluate the occurrence and genetic factors associated with high-grade irAEs.
- The findings revealed that certain genetic mutations in tumor samples were linked to a higher risk of high-grade irAEs, offering insights for treatment considerations and monitoring strategies.*